
Personalialia

Name Vandembroucke
Surname Roos(marijn) Els Jeanne Regina Stella
Place and date of birth Izegem (Belgium), 08/07/1979
Nationality Belgian
Home address Statiestraat 21, B-8720 Dentergem, BELGIUM
Telephone number +32-479-26.80.56
+32-51-68.75.70
E-mail Roosmarijn.Vandembroucke@irc.VIB-UGent.be
Civil status married – Lore °08/05/'06 & Febe °07/05/'08
Websites www.irc.ugent.be/index.php?id=roosvandembrouckehome
https://www.researchgate.net/profile/Roosmarijn_Vandembroucke

Job experiences & degrees

01/10/01 till 31/12/02 **PhD research** “Moleculaire karakterisering van het hEC-Rep1a eiwit: rol in celadhesie, translationele regulatie en Wnt-signalisatie” (IWT) - BELGIUM - UGhent, Faculty of Sciences, Department of Molecular Biomedical Research - Prof. dr. Frans Van Roy and Prof. dr. Geert Berx
01/01/03 till 30/09/08 **PhD research** “Non-viral Delivery Strategies to Guide Therapeutic Nucleic Acids through Cellular Barriers” (Research assistant) - BELGIUM - UGhent, Faculty of Pharmaceutical Sciences - Prof. dr. apr. N. Sanders, Prof. dr. apr. J. Demeester Prof. dr. apr. S. De Smedt
01/10/08 till 30/09/09 **Postdoctoral researcher** (BOF) - BELGIUM - Flemish Institute of biotechnology (VIB), Department of Molecular Biomedical Research, Molecular Mouse Genetics Unit (MMG) - Prof. dr. Claude Libert
2011-12 & 2012-13 **20% Lector** ‘Voedingswarenanalyse’ – Hogeschool Gent (Vesalius)
01/10/09 till 30/09/14 **Postdoctoral researcher** FWO - BELGIUM - Flemish Institute of biotechnology (VIB), Inflammation Research Center (IRC), Mouse Genetics in Inflammation Unit (MGI) - Prof. dr. Claude Libert
01/10/14 till 30/09/15 **Assistant Professor** - BELGIUM - Flemish Institute of biotechnology (VIB), Inflammation Research Center (IRC), Mouse Genetics in Inflammation Unit (MGI)
From 01/10/15 onwards **Associate Professor & Staff scientist** - BELGIUM – VIB-UGent Center for Inflammation Research, Barriers in Inflammation team

Degrees

O.L.V. ter Engelen instituut, Kortrijk Sciences-Maths (8)
KULAK, Kortrijk Bachelor Biology (July 1999)
Ghent University Master Biotechnology (with great distinction; July 2001)

Master thesis: “Analyse van de E-cadherine-gemedieerde differentiële gen expressie in humane borstkankercellen met behulp van de techniek ‘Molecular Indexing’ ” (Prof. dr. F. Van Roy & Prof. dr. G. Berx)

Doctor in Pharmaceutical Sciences (27/03/08): “Non-viral Delivery Strategies to Guide Therapeutic Nucleic Acids through Cellular Barriers” - “Niet-virale afgifte strategieën voor transfer van therapeutische nucleïnezuren doorheen cellulaire barrières” (Prof. dr. apr. N. Sanders, Prof. dr. apr. J. Demeester & Prof. dr. apr. S. De Smedt)

Carreer breaks

Sick leave

26/10/2009 – 31/12/2009 (surgery herniated disc)
10/01/2012 – 31/03/2012 (surgery herniated disc)
10/02/2006 – 30/04/2006 (complications pregnancy)

Pregnancy leave

01/05/2006 – 09/07/2006
25/04/2008 – 07/08/2008

Additional courses and workshops

Course ‘**Moleculaire Oncologie**’ (UGent; Dr. Geert Bercx)
Course ‘**Laboratory Animal Science part I and II**’ (UGent; Dr. Kathleen Hermans)
Several courses ‘**Geaggregeerde in de Biologie**’ (UGent)
“Onderwijs en maatschappij”
“Pedagogische componenten van het leraarschap”
“Educatieve interactie en communicatie”
“Maatschappelijke & wetenschapsfilosofische analyse van de vakinhouden”
Course ‘**Websites ontwerpen in html**’ (e-learning vdab)
Workshop ‘**Ensembl**’ (organisation DMBR)
Workshop ‘**Genevestigator training**’ (organisation VIB)
Workshop ‘**Ingenuity Pathway Analysis training**’ (organisation VIB)
Workshop ‘**Introduction to bioinformatics**’ (organisation VIB)
Workshop ‘**VectorNTI**’ (organisation DMBR)
Workshop ‘**Linux Emboss Bioperl**’ (organisation VIB; Luc Ducazu, Guy Bottu, Marc Logghe)
Workshop ‘**CLC DNA workbench**’ (organisation VIB)
Course ‘**Objectgeoriënteerde principes**’ (e-learning vdab)
Workshop ‘**Effective oral presentation**’ (2 days; organisation VIB and Principiæ; Jean-luc Doumont, Geneviève Casterman)
Workshop ‘**Leadership program for postdocs & staff scientist**’ (4 days; organisation VIB and True Colors)
Course ‘**Tech Transfer**’ (4 days; organization VIB Tech Transfer)
Workshop ‘**Female Research Careers**’ (5 days; organisation VIB & True Colors)
Workshop ‘**The essential guide to publishing in top tier journals**’ (organisation Leonie Welberg, Senior Editor on Nature Reviews Neuroscience, and Rachel Jones, trainer Macmillan Science Communications)
Course ‘**Creativity, pitching & resilience**’ (3 days; organisation UGent)
Course ‘**How to Write a Winning Grant Proposal**’ (2 days; organisation VIB)
Bachelor Bioinformatics (Bioinformatics@home; organisation HoWest)
Training ‘**Statistical Thinking and Smart Experimental Design**’ (organisation VIB)
Training ‘**Introduction to technologies for single cell analysis**’ (organisation VIB)
Training ‘**Precision Genome Engineering**’ – Ghent, Belgium (organisation VIB)

Training 'Therapeutic Proteins: Design and Applications' – Ghent, Belgium (organisation VIB)
Workshop 'PhD Coaching' (3 days; True Colors)

Mentoring PhD students

Dr. Lynda Grine, 01/01/2011 – 31/12/2014 (co-promotor)
Dr. Delphine Demeestere, 01/10/2011-31/12/2016 (promotor)
Dr. Marlies Ballegeer, 01/10/2011-31/12/2016 (co-promotor)
Dr. Sriram Balusu, 01/10/2012-30/04/2017 (promotor)

Sophie Steeland, start 01/10/2012 (co-promotor) – defense planned October 2017
Marjana Brkic, start 01/10/2013 (promotor; joint PhD Serbia)
Nina Gorlé, start 01/10/2014 (promotor)
Jolien Vandewalle, start 01/09/2014 (co-promotor)
Charysse Vandendriessche, start 01/10/2015 (promotor)
Eva Bauwens, start 01/10/2015 (co-promotor)
Arnout Bruggeman, start 01/10/2016 (promotor)

Fellowships and grants & awards

2001 PhD scholarchip (IWT) – own salary & €3.700/y bench fee
2008 Postdoc scholarship (BOF, UGent) - own salary & €5.000/y bench fee
2009 FWO postdoctoral scholarship & renewal (FWO) – own salary & €5.000/y bench fee
2011 Krediet aan Navorsers (FWO) - €22.000
IWT scholarship PhD student Lynda Grine (co-promotor) - salary & €3.700/y bench fee
2012 Krediet aan Navorsers (FWO) - €20.500
FWO postdoctoral scholarship renewal (FWO) - own salary & €5.000/y bench fee
IWT scholarship PhD student Delphine Demeestere (co-promotor) - salary & €3.700/y bench fee
VIB international PhD student scholarship Sriram Balusu (co-promotor) - salary & €3.700/y bench fee
FWO scholarship PhD student (co-promotor) Sophie Steeland - salary & €3.700/y bench fee
2013 Krediet aan Navorsers (FWO) - €20.000
2014 Award Foundation for Alzheimer Research (SAO-FRA) - €100.000
FWO project (FWO) - €270.000 totaal budget (€87.000)
Interdisciplinary Research Project (IOP) (Ghent University) - €400.000
Thrombogenics service contract – €30.000
2015 2x FWO scholarship PhD student Jolien Vandewalle en Charysse Vandendriessche - salary & €3.700/y bench fee
VIB Tech Transfer grant - €50.000 and €7.500
Krediet aan Navorsers (FWO) - €30.000
Vlaamse Parkinson liga - €18.000
2016 FWO scholarship PhD student Nina Gorlé - salary & €3.700/y bench fee
RIA Grant Horizon 2020 - ~€860.000 (total budget ~€6.000.000)
Starting grant UGent - salary PhD student & €3.700/y bench fee
2017 Grant Baillet Latour for Medical Research – €150.000/y for 3 yrs, extendable with 2 yrs

Awards

- 2009** **Poster award** - Gordon Research Conference - Matrix Metalloproteinases: Signalling Scissors In Development And Disease - Les Diablerets, Zwitserland
- 2011** **Poster award** - Gordon Research Conference - Matrix Metalloproteinases: Metalloproteinase Research at the Intersection of Basic Science and Applied Medicine - Smithfield, Rhode Island, USA
- 2013** **Poster award** - VIB Seminar - Blankenberge, Belgium
Young investigator travel award International Society of matrix Biology (ISMB) - Gordon Research Conference - Matrix Metalloproteinases - Il Ciocco, Italy
- 2015** **Poster award** - Cerebrovascular Biology (CVB) meeting in Paris, France
ISEV scholarship award - International Society of Extracellular Vesicles conference in Washington, USA
- 2017** **Baillet Latour for Medical Research** - Belgium

Memberships

2003-2008 member European society of gene and cell therapy (**ESGCT**)
 since 2012 member Society of Neuroscience (**SoN**)
 since 2013 member Belgian Immunology Society (**BIS**)
 since 2015 member International society of extracellular vesicles (**ISEV**)
 since 2015 member European society shock (**ESS**)
 since 2016 member European Crohn's and Colitis Organisation (**ECCO**)
 since 2015 member of the Ghent Gut Inflammation Group (**GGIG**)
 since 2016 nominated member **AcademiaNet**, a network with more than 2,000 excellent female researchers in all fields of academia from Europe

A1 publications

I currently have **72 peer-reviewed articles published** in international high impact journals. This results in an H-index of 23, as calculated by Web of Science. I'm **first or last author of 35 papers**. Additionally, **3 last author papers are currently submitted** and there are **2 last author papers in preparation**, which we aim to submit the coming months.

Total amount of publications	72
Sum of times cited	1841
Average Citations per item	25.57
H-index	23

- De Geest BG, **Vandenbroucke RE**, Guenther AM, Sukhorukov GB, Hennink WE, Sanders NN, Demeester J, De Smedt SC. Intracellularly degradable polyelectrolyte microcapsules. *Advanced Materials*. 2006 18 (8): 1005+. (**SCI-IF₂₀₀₆ = 7.896**; times cited: 205; **Q1**, 6/124)
- Lentacker I, De Geest BG, **Vandenbroucke RE**, Peeters L, Demeester J, De Smedt SC, Sanders NN. Ultrasound-responsive polymer-coated microbubbles that bind and protect DNA. *Langmuir*. 2006 Aug 15;22(17):7273-8. (**IF₂₀₀₆ = 3.902**; times cited: 91; **Q1**, 25/214)

3. Strumane K, Bonnomet A, Stove C, **Vandenbroucke R**, Nawrocki-Raby B, Bruyneel E, Mareel M, Birembaut P, Berx G, van Roy F. E-Cadherin Regulates Human Nanos1, which Interacts with p120ctn and Induces Tumor Cell Migration and Invasion. *Cancer Research*. 2006 Oct 15;66(20):10007-15. (**SCI-IF₂₀₀₆ = 7.656**; times cited: 14; **Q1**, 10/127)
4. von Gersdorff K, Sanders NN, **Vandenbroucke R**, De Smedt SC, Wagner E, Ogris M. The Internalization Route Resulting in Successful Gene Expression Depends on both Cell Line and Polyethylenimine Polyplex Type. *Molecular Therapy*. 2006 Nov;14(5):745-53. (**SCI-IF₂₀₀₆ = 5.841**; times cited: 175; **Q1**, 11/140)
5. **Vandenbroucke RE**, De Smedt SC, Demeester J, Sanders NN. Cellular entry pathway and gene transfer capacity of TAT-modified lipoplexes. *Biochimica et Biophysica Acta – Biomembranes*. 2007 Mar;1768(3):571-9. (**SCI-IF₂₀₀₇ = 3.640**; times cited: 49; **Q1**, 15/69)
6. Braeckmans K, Remaut K, **Vandenbroucke RE**, Lucas B, De Smedt SC and Joseph Demeester. Line FRAP with the confocal laser scanning microscope for diffusion measurements in small regions of 3-D samples. *Biophysical Journal*. 2007 Mar 15;92(6):2172-83. (**SCI-IF₂₀₀₇ = 4.627**; times cited: 42; **Q1**, 10/69)
7. **Vandenbroucke RE**, Lucas B, De Smedt SC, Demeester J, Sanders NN. Nuclear accumulation of plasmid DNA can be enhanced by non-selective gating of the nuclear pore. *Nucleic acids research*. 2007;35(12):e86. (**SCI-IF₂₀₀₇ = 6.954**; times cited: 19; **Q1**, 29/263)
8. **Vandenbroucke RE**, Lentacker I, Demeester J, De Smedt S and Sanders NN. Ultrasound assisted siRNA release using PEG-siPlex loaded microbubbles. *Journal of Controlled Release*. 2008 Mar 20;126(3):265-73. (**SCI-IF₂₀₀₈ = 5.690**; times cited: 68; **Q1**, 10/127)
9. Raemdonck K, Van Thienen TG, **Vandenbroucke RE**, Sanders NN, Demeester J and De Smedt SC. Dextran Microgels for Time-Controlled Delivery of siRNA. *Advanced Functional Materials*. 2008 Apr 11;18 (7):993-1001. (**SCI-IF₂₀₀₈ = 6.808**; times cited: 28; **Q1**, 6/113)
10. **Vandenbroucke RE**, De Geest BG, Bonn  S, Vinken M, Van Haecke T, Wagner E, De Smedt SC, Demeester J and Sanders NN. Prolonged gene silencing in hepatoma cells and primary hepatocytes after small interfering RNA delivery with biodegradable poly(beta-amino esters). *Journal of Gene Medicine*. 2008 Jul;10(7):783-94. (**SCI-IF₂₀₀₉ = 3.141**; times cited: 40; **Q2**, 63/146)
11. Fayazpour F, Lucas B, **Vandenbroucke RE**, Derveaux S, Tavernier J, Lievens S, Demeester J and De Smedt SC. Evaluation of digitally encoded layer-by-layer coated microparticles as cell carriers. *Advanced Functional Materials*. 2008 Sept;18(18):2716-2723. (**SCI-IF₂₀₀₈ = 6.808**; times cited: 7; **Q1**, 6/113)
12. Raemdonck K, **Vandenbroucke RE**, Sanders NN, De Smedt SC. Maintaining the silence: reflections on long-term RNAi. *Drug Discovery Today*. 2008 Nov;13(21-22):917-31. (**SCI-IF₂₀₀₈ = 6.618**; times cited: 46; **Q1**, 11/219)
13. Peeters L, Lentacker I, **Vandenbroucke RE**, Lucas B, Demeester J, Sanders NN and De Smedt SC. Can ultrasound solve the transport barrier of the neural retina? *Pharmaceutical research*. 2008 Nov;25(11):2657-65. (**SCI-IF₂₀₀₈ = 4.024**; times cited: 8; **Q1**, 40/237)
14. Lentacker I (*), **Vandenbroucke RE** (*), Lucas B, Demeester J, De Smedt SC and Sanders NN. New strategies for nucleic acid delivery to conquer cellular and nuclear membranes. *Journal of Controlled*

release. 2008 Dec 18;132(3):279-88. (**SCI-IF₂₀₀₈ = 5.690**; times cited: 29; **Q1**, 10/127) (*) both authors contributed equally

15. Nailis H, **Vandenbroucke RE**, Tilleman K, Deforce D, Nelis H and Coenye T. Monitoring ALS1 and ALS3 Gene Expression During In Vitro *Candida albicans* Biofilm Formation Under Continuous Flow Conditions. *Mycopathologia*. 2009 Jan;167(1):9-17. (**SCI-IF₂₀₀₉ = 1.728**; times cited: 28; **Q2**, 9/19)

16. Lentacker I, Wang N, **Vandenbroucke RE**, Vercauteren D, Demeester J, De Smedt SC and Sanders NN. Ultrasound Exposure of Lipoplex Loaded Microbubbles Facilitates Direct Cytoplasmic Entry of the Lipoplexes. *Molecular Pharmaceutics*. 2009 Mar-Apr;6(2):457-67. (**SCI-IF₂₀₀₉ = 5.408**; times cited: 51; **Q1**, 16/237)

17. Raemdonck K, Naeye B, Buyens K, **Vandenbroucke RE**, Högset A, Demeester J and De Smedt SC. Biodegradable dextran nanogels for RNA interference: focusing on endosomal escape and intracellular siRNA delivery. *Advanced Functional Materials*. 2009 May;19(9):1406-1415. (**SCI-IF₂₀₀₉ = 6.990**; times cited: 67; **Q1**, 11/214)

18. Vinken M, Decrock E, De Vuyst E, De Bock M, Leybaert L, **Vandenbroucke RE**, De Geest BG, Demeester J, Sanders NN, Vanhaecke T, Rogiers V. Connexin32 hemichannels facilitate the apoptotic-to-necrotic transition during Fas-mediated hepatocyte cell death. *Cellular and Molecular Life Sciences*. 2010 Mar;67(6):907-18 (**SCI-IF₂₀₁₀ = 7.047**; times cited: 18; **Q1**, 32/178)

19. Vercauteren D (*), **Vandenbroucke RE** (*), Demeester J, Rejman J, Jones AT, De Smedt SC, Sanders NN and Braeckmans K. Pitfalls in the use of inhibitors to study endocytic uptake of gene carriers. *Molecular Therapy*. 2010 Mar;18(3):561-9. (**SCI-IF₂₀₁₀ = 7.149**; times cited: 231; **Q1**, 7/106) (*) both authors contributed equally

20. Dejonckheere E, **Vandenbroucke RE** and Libert C. Matrix metalloproteinase 8 has a central role in inflammatory disorders and cancer progression. *Cytokine and growth Factor Reviews*. 2011. Apr;22(2):73-81. (**SCI-IF₂₀₁₁ = 7.812**; times cited: 34; **Q1**, 25/181)

21. **Vandenbroucke RE**, Dejager L, Libert C. The first MMP in sepsis. *EMBO Mol Med*. 2011. Jul;3(7):367-9. (**SCI-IF₂₀₁₁ = 10.333**; times cited: 8; **Q1**, 6/112)

22. Dejonckheere E, **Vandenbroucke RE** and Libert C. Matrix metalloproteinases as drug targets in ischemia/reperfusion injury. *Drug Discovery Today*. 2011. Sep;16(17-18):762-78. (**SCI-IF₂₀₁₁ = 6.828**; times cited: 40; **Q1**, 11/261)

23. Van Hauwermeiren F, **Vandenbroucke RE** and Libert C. Treatment of TNF mediated diseases by selective inhibition of soluble TNF or TNFR1. *Cytokine and growth Factor Reviews*. 2011. Oct-Dec;5-6:311-19. (**SCI-IF₂₀₁₁ = 7.812**; times cited: 51; **Q1**, 25/181)

24. **Vandenbroucke RE**, Dejonckheere E and Libert C. A therapeutic role for MMP inhibitors in lung diseases? *European Respiratory Journal*. 2011. Dec;38(5):1200-14. (**SCI-IF₂₀₁₁ = 5.895**; times cited: 37; **Q1**, 3/48)

25. De Temmerman M, Dewitte H, **Vandenbroucke RE**, Lucas B, Libert C, Demeester J, De Smedt SC, Lentacker I and Rejman J. mRNA-Lipoplex loaded microbubble contrast agents for ultrasound-assisted transfection of dendritic cells. *Biomaterials*. 2011. Dec;32(34):9128-35 (**SCI-IF₂₀₁₁ = 7.404**; times cited: 33; **Q1**, 1/25)

26. Van de Ven H, Vermeersch M, **Vandenbroucke RE**, Matheussen A, Apers S, Weyenberg W, De Smedt S, Cos P, Maes L, Ludwig A. Intracellular drug delivery in Leishmania-infected macrophages: evaluation of saponin-loaded PLGA nanoparticles. *Journal of Drug Targeting*. 2012. Feb;20(2):142-54. (**SCI-IF₂₀₁₂ = 2.768**; times cited: 9; **Q2**, 91/261)
27. De Temmerman M, Rejman J, **Vandenbroucke RE**, De Koker S, Libert C, Grooten J, Demeester J, Gander B and De Smedt S. Polyelectrolyte LbL microcapsules versus PLGA microparticles for immunization with a protein antigen. *Journal of Controlled Release*. 2012. Mar 10;158(2):233-9. (**SCI-IF₂₀₁₂ = 7.633**; times cited: 11; **Q1**, 10/261)
28. **Vandenbroucke RE**, Dejonckheere E, Van Lint P, Demeestere D, Van Wonterghem E, Vanlaere I, Puimège L, Van Hauwermeiren F, De Rycke R, Mc Guirre C, Campestre C, Matthys P, Leclercq G, López-Otin C, and Libert C. Matrix metalloprotease 8-dependent extracellular matrix cleavage at the blood-CSF barrier contributes to lethality during systemic inflammatory diseases. *Journal of Neuroscience*. 2012. Jul 18;32(29):9805-16. (**SCI-IF₂₀₁₂ = 6.908**; times cited: 37; **Q1**, 22/252)
29. De Temmerman M, Rejman J, Lucas B, **Vandenbroucke RE**, Libert C, Demeester J and De Smedt SC. Modulation of dendritic cells by lipid grafted polyelectrolyte microcapsules. *Advanced functional materials*. 2012 Oct 23;22(20): 4236-43. (**SCI-IF₂₀₁₂ = 10.342**; times cited: 3; **Q1**, 6/69)
30. Van Hauwermeiren F, Karagianni N, Kranidioti K, **Vandenbroucke RE**, Loges S, Van Roy M, Staelens J, Puimège L, Zhang H, Vanden Berghe W, Victoratos P, Carmeliet P, Kollias G and Libert C. Safe TNF-based antitumor therapy following p55TNFR reduction in intestinal epithelium. *Journal of Clinical Investigation*. 2013. Jun 3;123(6):2590-603. (**SCI-IF₂₀₁₂ = 13.77**; times cited: 18; **Q1**, 4/121)
31. **Vandenbroucke RE**, Dejonckheere E, Van Hauwermeiren F, Lodens S, De Rycke R, Van Wonterghem E, Staes A, Gevaert K, Lopez-Otin C, and Libert C. MMP13 contributes to intestinal barrier permeability via TNF cleavage. *EMBO Molecular Medicine*. 2013. Jul;5(7):1000-16. (**SCI-IF₂₀₁₃ = 8.25**; times cited: 35; **Q1**, 8/124)
- Highlighted in** Becker-Pauly C and Rose-John S. TNF α cleavage beyond TACE/ADAM17: matrix metalloproteinase 13 is a potential therapeutic target in sepsis and colitis. *EMBO Molecular Medicine*. 2013 Jul;5(7):970-2.
32. Vanhooren V, **Vandenbroucke RE**, Dewaele S, Van Hamme E, Haigh J, Hochepped T, Libert C. Mice overexpressing β -1,4-galactosyltransferase I are resistant to TNF-induced inflammation and DSS-induced colitis. *Plos One*. 2013 Dec 5;8(12):e79883. (**SCI-IF₂₀₁₃ = 3.53**; times cited: 3; **Q1**, 8/55)
33. Vandevyver S, Dejager L, **Vandenbroucke RE**, Claude Libert. An acute phase protein ready to go therapeutic for sepsis. *EMBO Molecular Medicine*. 2014 Jan 1;6(1):2-3. (**SCI-IF₂₀₁₄ = 8.665**; times cited: 11; **Q1**, 9/123)
34. Temmerman M, Soenen SJ, Symens N, Lucas B, **Vandenbroucke RE**, Libert C, Demeester J, De Smedt S, Himmelreich U, Rejman J. Magnetic layer-by-layer coated particles for efficient magnetic resonance imaging of dendritic cells and mesenchymal stem cells. *Nanomedicine*. 2014 Jul;9(9):1363-76. (**SCI-IF₂₀₁₄ = 5.413**; times cited: 1; **Q1**, 16/163)
35. De Bock M (*), **Vandenbroucke RE** (*), Decrock E, Culot M, Cecchelli R, and Leybaert L. A new angle on blood-CNS interfaces: A role for connexins? *FEBS letters* 2014 Apr 17;588(8):1259-1270. (**SCI-IF₂₀₁₄ = 3.169**; times cited: 17; **Q2**, 100/184) (*) both authors contributed equally

36. **Vandenbroucke RE**, Vanlaere I, Van Hauwermeiren F, Van Wonterghem E, Wilson C, and Libert C. Pro-inflammatory effects of matrix metalloproteinase 7 in acute inflammation. *Mucosal Immunology*. 2014 May;7(3):579-88. (SCI-IF₂₀₁₄ = **7.374**; times cited: 14; **Q1**, 14/148)
37. Van Hauwermeiren F, **Vandenbroucke RE**, Gryne L, Puimège L, Van Wonterghem E, Zhang H, Libert C. Antisense oligonucleotides against TNFR1 prevent toxicity of TNF/IFN γ treatment in mouse tumor models. *International Journal of Cancer*. 2014. August;135(3):742-750. (SCI-IF₂₀₁₄ = **5.085**; times cited: 4; **Q1**, 31/211)
38. Laukens D, Devisscher L, Van den Bossche L, Hindryckx P, Vandewynckel Y, **Vandenbroucke RE**, Cuvelier C, Brinkman BM, Libert C, Vandenabeele P and De Vos M. Tauroursodeoxycholic acid inhibits experimental colitis by preventing early intestinal epithelial cell death. *Lab Invest*. 2014. Dec;94(12):1419-30. (SCI-IF₂₀₁₄ = **3.676**; times cited: 7; **Q1**, 30/123)
39. **Vandenbroucke RE**, Libert C. Is there new hope for therapeutic matrix metalloproteinase inhibition? *Nature Reviews Drug Discovery*. 2014. Dec;13(12):904-27 (SCI-IF₂₀₁₄ = **41.908**; times cited: 108; **Q1**, 1/255)
40. Dewitte H, Verbeke R, Breckpot K, **Vandenbroucke RE**, Libert C, De Smedt SC, Lentacker I. Choose your models wisely: The way dendritic cells are derived from murine bone marrow influences the in vitro performance of nanoparticulate vaccines. *Journal of Controlled release*. 2014 Jun 21. pii: S0168-3659(14)00423-4. (SCI-IF₂₀₁₄ = **7.705**; times cited: 5; **Q1**, 10/255)
41. Aerts J (*), **Vandenbroucke RE** (*), Dera R, Balusu S, Van Wonterghem E, Moons L, Libert C, Dehaen W and Arckens L. Synthesis and validation of a hydroxypyrrone-based, highly specific matrix metalloproteinase-12 inhibitor with anti-inflammatory activity in vitro and in vivo. *Mediators of inflammation*. 2015. (SCI-IF₂₀₁₅ = **3.418**; times cited: 1; **Q2**, 58/148) (*) both authors contributed equally
42. De Groef L, Salinas-Navarro M, Van Imschoot G, Libert C, **Vandenbroucke RE**, and Moons L. Decreased TNF levels and improved retinal ganglion cell survival in MMP-2 null mice suggest a role for MMP-2 as TNF sheddase. *Mediators of inflammation*. 2015. 2015:108617. (SCI-IF₂₀₁₅ = **3.418**; times cited: 2; **Q2**, 88/187)
43. Brkic M, Balusu S, Libert C, and **Vandenbroucke RE**. Friends or foes: matrix metalloproteinase and their multifaceted roles in neurodegenerative diseases. *Mediators of inflammation*. 2015. 2015/620581. (SCI-IF₂₀₁₅ = **3.418**; times cited: 5; **Q2**, 88/187)
44. Timmermans S, Van Hauwermeiren F, Puimège L, Dejager L, Van Wonterghem E, Vanhooren V, Vandesompele J, Libert C, **Vandenbroucke RE**. Determining differentially expressed miRNAs and validating miRNA-target relationships using the *SPRET/Ei* mouse strain. *Mammalian Genome*. 2015 Feb;26(1-2):94-107 (SCI-IF₂₀₁₅ = **2.078**; times cited: 2; **Q3**, 199/289)
45. Gryne L, Dejager L, Libert C and **Vandenbroucke RE**. An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17. *Cytokine and growth Factor Reviews*. *Cytokine Growth Factor Reviews*. 2015 Feb;26(1):25-33 (SCI-IF₂₀₁₅ = **6.571**; times cited: 20; **Q1**, 32/289)
46. Steeland S, Puimège L, **Vandenbroucke RE**, Van Hauwermeiren F, Hastraete J, Devoogdt N, Hulpiau P, Leroux-Roels G, Laukens D, Meuleman P, De Vos M and Libert C. Generation and characterization of small single domain antibodies inhibiting human TNF receptor 1. *Journal of Biological Chemistry*. *Journal Biological Chemistry*. 2015 Feb 13;290(7):4022-37. (SCI-IF₂₀₁₅ = **4.258**; times cited: 8; **Q1**, 71/289)

47. Gryne L, Dejager L, Libert C and **Vandenbroucke RE**. Dual inhibition of TNFR1 and IFNAR1 in imiquimod-induced psoriasis enhances control of the disease. *Journal of Immunology*. 2015 Jun 1;194(11):5094-102. (**SCI-IF₂₀₁₅ = 4.985**; times cited: 6; **Q1**, 32/150)
48. Van Hauwermeiren F (*), **Vandenbroucke RE** (*), Gryne L, De Rycke R, Kollias G, Libert C. TNFR1-induced lethal inflammation is mediated by goblet and Paneth cell dysfunction. *Mucosal Immunology*. 2015 Jul;8(4):828-40. (**SCI-IF₂₀₁₅ = 6.103**; times cited: 3; **Q1**, 23/150) (*) both authors contributed equally
49. Vanden Berghe T, Hulpiau P, Martens L, **Vandenbroucke RE**, Perry SW, Bruggeman T, Divert T, Choi SM, Shestopalov VI, Libert C and Vandenabeele P. Passenger mutations confound interpretation of transgenic strain data. *Immunity*. 2015 Jul 21;43(1):200-9. (**SCI-IF₂₀₁₅ = 24.082**; times cited: 33; **Q1**, 3/150)
50. Puimège L, Van Hauwermeiren F, Lodens S, Dejager L, Steeland S, Vandevyver S, Staelens J, Timmermans S, **Vandenbroucke RE** (*) and Libert C (*). MicroRNA-511 is induced by glucocorticoids and protects against TNF by down-regulating TNFR1. *EMBO Molecular Medicine* 2015 May 20;7(8):1004-17. (**SCI-IF₂₀₁₅ = 9.547**; times cited: 8; **Q1**, 7/124) (*) both authors contributed equally
51. Demeestere D, Libert C and **Vandenbroucke RE**. Clinical implications of leukocyte infiltration at the choroid plexus in (neuro)inflammatory disorders. *Drug Discovery Today*. 2015 Aug;20(8):928-41. (**SCI-IF₂₀₁₅ = 5.625**; times cited: 7; **Q1**, 13/253)
52. Brkic M, Balusu S, Van Wonterghem E, Gorlé N, Benilova I, Kremer A, Van Hove I, Moons L, De Strooper B, Kanazir S, Libert C, and **Vandenbroucke RE**. Amyloid β oligomers disrupt blood-cerebrospinal fluid barrier integrity by activating matrix metalloproteinases. *Journal of Neuroscience*. 2015 Sep 16;35(37):12766-78. (**SCI-IF₂₀₁₅ = 5.924**; times cited: 17; **Q1**, 26/256)
Highlighted on 'Atlas of science' (<http://atlasofscience.org/should-we-protect-the-brain-barriers-to-prevent-alzheimers-disease/>) and Alzforum (<http://www.alzforum.org/news/research-news/barriers-between-blood-and-csf-brain-yield-av-not-bad-thing>)
53. Demeestere D, Libert C, and **Vandenbroucke RE**. Therapeutic implications of the choroid plexus-cerebrospinal fluid interface in neuropsychiatric disorders. *Brain, behavior and immunity*. 2015 Jun 23. pii: S0889-1591(15)00163-4. (**SCI-IF₂₀₁₅ = 5.874**; times cited: 1; **Q1**, 27/256)
54. Sklyarova T, van Hengel J, Van Wonterghem E, Libert C, van Roy F, and **Vandenbroucke RE**. Hematopoietic plakophilin-3 regulates acute tissue-specific and systemic inflammation in mice. *European Journal of Immunology*. 2015 Oct;45(10):2898-910. (**SCI-IF₂₀₁₅ = 4.179**; times cited: 3; **Q2**, 42/150)
55. Storck SE, Meister S, Nahrath J, Meißner JN, Schubert N, Di Spiezio A, Baches S, **Vandenbroucke RE**, Bouter Y, Prikulis I, Korth C, Weggen S, Heimann A, Schwaninger M, Bayer TA and Pietrzik CU. Endothelial-LRP1 clears major amounts of A β 1-42 across the blood-brain barrier. *Journal of Clinical Investigation*. 2016 Jan 4;126(1):123-36. (**SCI-IF₂₀₁₅ = 12.575**; times cited: 16; **Q1**, 3/124)
56. Grine L, Steeland S, Lienenklaus S, Van Ryckeghem S, Sanders NN, **Vandenbroucke RE** (*) and Claude Libert (*). Topical imiquimod yields systemic effects due to unintended oral uptake. *Scientific reports*. 2016 Jan 28;6:20134. (**SCI-IF₂₀₁₅ = 5.228**; times cited: 1; **Q1**, 7/63) (*) both authors contributed equally

57. Balusu S, Brkic M, Libert C and **Vandenbroucke RE**. The choroid plexus - cerebrospinal fluid interface in Alzheimer's disease: a barrier and so much more. *Neural Regeneration Research*. 2016. Apr;11(4):534-7. (**SCI-IF₂₀₁₅ = 0.968**; times cited: 2; **Q4**, 232/256)
58. Kessler SM, Laggai S, Van Wonterghem E, **Vandenbroucke RE**, Ogris M, Libert C and Kiemer AK. Transient hepatic overexpression of IGF2 induces lipid droplet formation. *Frontiers in Physiology*. 2016. Apr 25;7:147. (**SCI-IF₂₀₁₅ = 4.031**; times cited: 1; **Q1**, 14/83)
59. Demeestere D, Dejonckheere E, Steeland S, Hulpiau P, Haustraete J, Devoogdt N, Wichert R, Becker-Pauly C, Van Wonterghem E, Dewaele S, Aerts J, Arckens L, Saeys Y, Libert C, and **Vandenbroucke RE**. Development and validation of a small single domain antibody that effectively inhibits matrix metalloproteinase 8. *Molecular Therapy*. 2016 May;24(5):890-902. (**SCI-IF₂₀₁₅ = 6.938**; times cited: 1, **Q1**, 11/161)
60. Steeland S, Timmermans S, Van Ryckeghem S, Hulpiau P, Saeys Y, van Montagu M, **Vandenbroucke RE (*)** and Libert C (*). Efficient analysis of whole genome sequences reveal inbred mouse strains as resources of mutant alleles: the case of SPRET/Ei. *PNAS*. May 17;113(20):5670-5. (*) both authors contributed equally (**SCI-IF₂₀₁₅ = 9.423**; times cited: 0, **Q1**, 4/63)
61. Grine L, Libert C, and **Vandenbroucke RE**. Comment on "TNF α plays a significant role in the Aldara-induced skin inflammation in mice". *British Journal of Dermatology*. 2016 Jun;174(6):1419-20. (**SCI-IF₂₀₁₅ = 4.317**; times cited: 1; **Q1**, 5/61)
62. Stremersch S, **Vandenbroucke RE**, Van Wonterghem E, Hendrix A, De Smedt SC, Raemdonck K. Questioning exosome-like vesicles as a universal siRNA delivery vehicle. *Journal of Controlled Release*. 2016. Apr 9;232:51-61 (**SCI-IF₂₀₁₅ = 7.441**; times cited: 4; **Q1**, 9/253)
63. Steeland S, **Vandenbroucke RE (*)** and Libert C (*). Nanobodies as therapeutics: small antibodies have grown big. *Drug Discovery Today*. 2016 Jul;21(7):1076-113 (**SCI-IF₂₀₁₅ = 5.625**; times cited: 3; **Q1**, 13/253) (*) both authors contributed equally
64. De Bock M, Van Haver V, **Vandenbroucke RE**, Decrock E and Leybaert L. Into unexplored terrain - Transcellular transport across the blood-brain barrier. *Glia*. 2016. Jul;64(7):1097-123. (**SCI-IF₂₀₁₅ = 5.997**; times cited: 2; **Q1**, 25/256)
65. Van Cauwenberghe C, Vandendriessche C, Libert C, **Vandenbroucke RE**. Caloric restriction: beneficial effects on brain aging and Alzheimer's disease. *Mammalian Genome*. 2016 Aug;27(7-8):300-19. (**SCI-IF₂₀₁₅ = 2.078**; times cited: 3; **Q3**, 199/289)
66. Gorlé N, Van Cauwenberghe C, Libert C and **Vandenbroucke RE**. The effect of aging on brain barriers and the consequences for Alzheimer's disease development. *Mammalian Genome*. 2016 Aug;27(7-8):407-20. (**SCI-IF₂₀₁₅ = 2.078**; times cited: 6; **Q3**, 199/289)
67. Xiong R, **Vandenbroucke RE**, Broos K, Van Wonterghem E, Libert C, Demeestere J, De Smedt S and Braeckmans K. FRAP for measuring continuous nano-size distribution: from sizing protein in biological fluids to characterizing macromolecule vascular and intestinal permeability. *Nature Communications*. 2016 2016 Sep 22; 7:12982. (**SCI-IF₂₀₁₅ = 11.329**; times cited: 0; **Q1**, 3/63)
68. Balusu S, Van Wonterghem E, De Rycke R, Raemdonck K, Stremersch S, Gevaert K, Brkic M, Demeestere D, Vanhooren V, Hendrickx A, Libert C and **Vandenbroucke RE**. Identification of a novel mechanism of blood-brain communication during peripheral inflammation via choroid plexus derived

extracellular vesicles. *EMBO molecular medicine*. 2016 Oct 4;8(10):1162-1183 (**SCI-IF₂₀₁₅ = 9.547; Q1, 7/124**)

69. Van Hove I, Lefevre E, De Groef L, Sergeys J, Salinas-Navarro M, Libert C, **Vandenbroucke RE**, Moons L. MMP-3 Deficiency Alleviates Endotoxin-Induced Acute Inflammation in the Posterior Eye Segment. *International Journal of Molecular Science*. 2016 Nov 1; 17(11) (**SCI-IF₂₀₁₅ = 3.257; times cited: 0; Q2, 110/289**)

70. Köks S, Dogan S, Tuna BG, González-Navarro H, Potter P and **Vandenbroucke RE**. Mouse models of ageing and their relevance to disease. *Mechanisms of ageing and development. Mechanisms of Ageing and Development*. 2016 Dec; 160:41-53. (**SCI-IF₂₀₁₅ = 2.892; times cited: 0; Q2, 104/187**)

71. Drechsler S, Lynch MA, Novella S, González-Navarro H, Hecimovic S, Barini E and Tucci V, Castro RE, **Vandenbroucke RE**, Osuchowski M, Potter PK. With mouse age comes wisdom: a review and suggestions of relevant mouse models for age-related changes and diseases. *Mechanisms of ageing and development. Mech Ageing Dev*. 2016 Dec; 160:54-68. (**SCI-IF₂₀₁₅ = 2.892; times cited: 0; Q2, 104/187**)

72. **Vandenbroucke RE**. A Hidden Epithelial Barrier in the Brain with a Central Role in Regulating Brain Homeostasis. Implications for Aging. *Annals of the American Thoracic Society*. 2016 Dec; 13(13 Suppl 5):S407-S410. (no IF yet; times cited: 0)

C1 publications

1. **Vandenbroucke R**, Lucas B, Demeester J, De Smedt S and Sanders, N. Nuclear accumulation of plasmid DNA can be enhanced by non-selective gating of the nuclear pore. *Human Gene Therapy*. 2007 October 1, 18(10): 973-973. (**SCI-IF₂₀₀₉ = 4.202**)

2. **Vandenbroucke R**, Lentacker I, Demeester J, De Smedt S and Sanders N. Loading of PEGylated siRNA lipoplexes on microbubbles restores their siRNA delivery capacity in the presence of ultrasound. *Human Gene Therapy*. 2007 October 1, 18(10): 1046-1046. (**SCI-IF₂₀₀₉ = 4.202**)

3. **Vandenbroucke R**, De Geest B, Demeester J, De Smedt S and Sanders, N. Prolonged gene silencing in hepatoma cells and primary hepatocytes after siRNA delivery with biodegradable poly(β -amino ester)s. *Human Gene Therapy*. 2007 October 1, 18(10): 1056-1056. (**SCI-IF₂₀₀₉ = 4.202**)

4. Fayazpour F, Lucas B, Huyghebaert N, Braeckmans K, Derveaux S, **Vandenbroucke R**, Remon JP, Demeester J, Vervaet C and De Smedt S. Opportunities for digitally encoded microcarriers in pharmacy and cell-based assays. *European Journal of Pharmaceutical Sciences*. 2009 June 9, 34(1): S29-S29. (**SCI-IF₂₀₀₉ = 2.608**)

5. Vercauteren D, Vandenbroucke RE, Demeester J, De Smedt SC, Braeckmans K and Sanders NN. The use of endocytic inhibitors to study uptake of gene carriers. *Journal of Controlled Release*. 2008 Dec 18, 132(3): E17-18. (**SCI-IF₂₀₀₉ = 5.949**)

6. **Vandenbroucke R**, Vanlaere I, Dejonckheere E, Van Lint P, Libert C. Link between MMP-7 and IL-1 beta release in endotoxemia. *Inflammation Research*. 2010 59: S121-S122 (**SCI-IF₂₀₁₀ = 2.004**)

7. Grine L, **Vandenbroucke R**, Dejager L, Libert C. A combined role for TNFR1 and IFNAR1 in psoriasis? *Cytokine*. 2012 59(3): 548-548 (**IF₂₀₁₂ = 3.019**)

8. **Vandenbroucke RE**, Dejonckheere E, Demeestere D, Van Wonterghem E, Puimege L, Van Hauwermeiren F, De Rycke R, McGuire C and Libert C. MMP8 contributes to lethality during systemic inflammatory diseases. *Experimental Gerontology*. 2013 July, 48(7): 686-686. **(SCI-IF₂₀₁₃ = 3.529)**
9. Blaecher C, Gorle N, Bauwens E, Flahou B, Ducatelle R, Libert C, **Vandenbroucke R**, Haesebrouck F, Smet, A. Influence of the stomach-brain axis in relation to an experimental *Helicobacter suis* infection in mice. *Helicobacter*. 2016 20(S11): 84-84. **(SCI-IF₂₀₁₃ = 3.920)**

Patents

CLi/MMP8INH/358 - MMP8 inactivating antigen binding proteins - Claude Libert, Eline Dejonckheere and Roosmarijn Vandenbroucke
CLi/MMP8TNFR1/562 - Means and methods to treat inflammation - Claude Libert, Sophie Steeland and Roosmarijn Vandenbroucke

Editorial activities in foreign laboratories

Referee Funding agencies

FWO Vlaanderen (panel member Bio2 since 2016)

Referee Journals (2016 and 2017)

EMBO Molecular Medicine, Journal of Controlled Release, Acta Neuropathologica, Mucosal Immunology, Scientific Reports, Acta Biomaterialia, Alzheimer's Research & Therapy, Journal of Molecular Medicine, Journal of Neuroscience Research, Infectious Diseases, Plos One, Immunology and Cell Biology, Neuroscience Letters, American Journal of Respiratory and Critical Care Medicine, Journal of Translational Medicine, European Respiratory Journal,...

Editorial Activities

Science Matters

Stays in foreign laboratories

January 22th - February 6th 2004 - Corbett Lab, Emory University - Atlanta, Georgia, United States - "NLS-importin interactions"

August 5th – 7th 2005 - Prof. Pepperkok, EMBL Heidelberg, Duitsland - "Micro-injection and CLSM"

April 9th – 16th 2010 - EMBL course "miRNA profiling", Monterotondo, Italy

October 15th – 29th 2011 - Facultad de Ciencias Químicas, Departamento de Bioquímica Clínica, Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Córdoba, Argentina

Conferences and seminars

I was co-chair of the 'Meeting on blood-brain interfaces' (Arras, France) in 2014, co-organizer of the COST MouseAge workshop and conference in Braga (Portugal) in 2015 and I was chair of the Gordon Research Seminar 'Barriers to the CNS' that took place in Boston (USA) in June 2016.

Additionally, I'm substitute member of the European 'Me-Had' COST action and active member of the 'MouseAge' **COST action**, where I'm part of the Core group as deputy work group leader, Early Stage Researcher coordinator and I'm responsible for the organization of short term scientific missions.

Since the start of my PhD studies, I attended **~120 national and international seminars and conferences**, in most of which I actively contributed by oral or poster presentations. I have given **~50 oral presentations**, of which **~30 were by invitation** from different parts of the world, for example from The Netherlands, Spain, Argentina, Serbia, Croatia, Australia, Sweden and UK.

2001

Belgian-Dutch Meeting on Cell Adhesion - Ghent, Belgium - poster presentation

2003

EMBO Practical Course and Minisymposium - EMBL Heidelberg, Germany - poster presentation

Autumn Meeting of the Belgian-Dutch Biopharmaceutical Society - Universiteit Groningen, The Netherlands - oral presentation

Spring Meeting of the Belgian-Dutch Biopharmaceutical Society - Utrecht, The Netherlands

2004

Congress on Peptide-Membrane Interactions - Namen, België - poster presentation

The Wilhelm Bernard Workshop, 18th International Workshop on the Cell Nucleus - Pavia, Italy - oral presentation

8th European Symposium on Controlled Drug Delivery - Noordwijk aan Zee, The Netherlands

2005

ASGT 8th Annual Meeting - St. Louis, MO, USA - poster & oral presentation

Pepvec2005 "Mechanism of carrier-mediated intracellular delivery of therapeutics" – Montpellier, France - poster presentation

Autumn Meeting of the Belgian-Dutch Biopharmaceutical Society - Universiteit Utrecht, The Netherlands - oral presentation

2006

Autumn Meeting of the Belgian-Dutch Biopharmaceutical Society - Universiteit Leiden, The Netherlands - oral presentation

2007

Pre-Satellite Meeting of the 3rd Pharmaceutical Sciences World Congress (PSWC 2007) – Amsterdam, The Netherlands - poster presentation

ASGT 10th Annual Meeting - Seattle, USA - poster & oral presentation

7th International Symposium on Frontiers in Biomedical Polymers - Gent, Belgium - poster presentation

ESGCT 15th Annual Meeting – Rotterdam, The Netherlands - poster & oral presentation

GTRV Summer School – Grenoble, France - oral presentation

2nd Cell Signaling and Bioluminescence Seminar – Brussel, Belgium - invited oral presentation

Material Challenges for Biomedical Applications Symposium – Gent, Belgium - oral presentation

FWO Minisymposium on Nuclear Import – Gent, Belgium – invited oral presentation

2008

10th European Symposium on Controlled Drug Delivery (ESCDD) – Noordwijk aan Zee, The Netherlands - poster presentation

RNAi - The RIGHT Track to Therapy - Brussels, Belgium

The Annual BIS meeting - Luik, Belgium

ASGT 11th Annual Meeting - Boston, USA - poster presentation

10th European Symposium on Controlled Drug Delivery (ESCDD) – Noordwijk aan Zee, The Netherlands - oral presentation

11th annual meeting of the American Society of Gene Therapy (ASGT) – Boston, USA - oral presentation

3rd eSI Workshop – Alicante, Spain - invited oral presentation

2009

Matrix Metalloproteinases - Signalling Scissors In Development And Disease – Les Diablerets, Switzerland - poster presentation

Annual BACR meeting - Anderlecht, Belgium

Mouse Models - Leiden, The Netherlands

2010

The 8th World Congress on Trauma, Shock, Inflammation and Sepsis, TSIS 2010 – München, Germany - poster presentation

RNAi and miRNA Europe – Dublin, Ireland - poster presentation

Seminar, Universiteit van Groningen – Groningen, The Netherlands - invited oral presentation

2011

Gordon Research Conference – Matrix Metalloproteinases: Metalloproteinase Research at the Intersection of Basic Science and Applied Medicine – Smithfield, Rhode Island, USA - poster presentation

Seminar, Facultad de Ciencias Químicas, Departamento de Bioquímica Clínica - Córdoba, Argentina – invited oral presentation

BIS Autumn Meeting - Hasselt University Campus Diepenbeek, Belgium - poster presentation

VIB seminar 2011 – Blankenberge, Belgium

EMBO Molecular Medicine “Molecular Insights for Innovative Therapies” - Heidelberg, Germany - poster presentation

IAP meeting - Ghent, Belgium

2012

Cell Adhesion and Cell Polarity in Development and Disease, Spring Meeting BSCDB – Ghent, Belgium – invited oral presentation

Gordon Research Conference – Barriers of the CNS – New London, NH, USA – poster presentation

The 11th International Symposium on Neurobiology and Neuroendocrinology of Aging - Bregenz, Austria – poster presentation

VIB seminar 2012 – Blankenberge, Belgium

Seminar ‘Janssen Pharmaceutica: pipeline and future leads in oncology, infectious diseases and CNS’ – Beerse, Belgium

2013

IUAP meeting Discobel – Ghent, Belgium – oral presentation

Barriers of the CNS conference 2013 – Lanzarote, Spain – oral presentation

Meeting on blood-brain interfaces – Arras, France – **co-chair**, oral presentation

Gordon Research Seminar - Matrix Metalloproteinases: Key Mediators of Biological Processes from Development to Disease– Lucca, Italy – oral presentation

VIB seminar 2013 – Blankenberge, Belgium

Gordon Research Conference – Matrix Metalloproteinases: Crucial Components of Molecular Networks and Disease Pathways – Lucca, Italy – oral presentation

Belgian Society for Cell and Developmental Biology Meeting ‘Experimental Models of Human Diseases’ – Luik, Belgium – oral presentation

VI Congress of Serbian Neuroscience Society – Belgrado, Serbia – invited oral presentation (Prof. Selma Kanazir)

2014

IUAP meeting Discobel – Spa, Belgium – oral presentation
Workshop and symposium From 3D Light to 3D Electron Microscopy – poster presentation
International Society of Extracellular Vesicles (ISEV) 2014 – Rotterdam, The Netherlands – oral presentation
Inflammation Research Center (IRC) seminar 2014 – Ghent, Belgium – oral presentation
Gordon Research Seminar - Barriers of the CNS – New London, NH, USA – oral presentation
Gordon Research Conference - Barriers of the CNS – New London, NH, USA – poster presentation
VIB seminar 2014 – Blankenberge, Belgium
Seminar - Oxford University – Oxford, UK – invited oral presentation (Prof. Matthew Wood)
9th ISNIM Congress – Liege, Belgium – poster presentation
The 12th International Symposium on Neurobiology and Neuroendocrinology of Aging - Bregenz, Austria – poster presentation
Seminar 'Partnering opportunities in oncology, infectious diseases and CNS' – Hasselt, Belgium
Symposium 'The Emerging Power of Quantitative Proteomics in Life Sciences' – Ghent, Belgium
qPCR mini-symposium – Ghent, Belgium
Symposium on 'System-wide Networks in Immunology' – Ghent, Belgium
Symposium 'Drug Discovery Anno 2014: from target identification to personalized medicine' – Leuven, Belgium
Annual BIS meeting – Ghent, Belgium
Symposium 'New Frontiers in Neuroimaging' – Hasselt, Belgium

2015

Seminar – Karolinska Institutet – Stockholm, Sweden – invited oral presentation (Prof. Samir El-Andaloussi)
International Society of Extracellular Vesicles (ISEV) 2015 – Washington DC, US – oral presentation
IUAP meeting Discobel – Leuven, Belgium – poster presentation
11th meeting of the Belgian Society for Neuroscience – University of Mons, Belgium – poster presentation
EMBO Symposium Mechanisms of Neurodegeneration - Heidelberg, Germany – poster presentation
11th International Conference on Cerebral Vascular Biology (CVB) meeting – Paris, France – poster presentation
VIB seminar 2015 – Blankenberge, Belgium – poster presentation
Seminar – University of Mainz – Mainz, Germany – invited oral presentation (Prof. Claus Pietrzik)
Seminar – University of Hasselt – Hasselt, Belgium – invited oral presentation (Prof. Sven Hendrix)
Seminar – Ludwig Boltzmann Institute – Vienna, Austria – invited oral presentation (Prof. Marcin Osuchowski)
XVIth congress of the European Shock Society – Cologne, Germany – invited oral presentation
FENS Featured Regional Meeting 2015 - Thessaloniki , Greece – invited oral presentation
PhD student course "Extracellular vesicle: a tool for diagnostics, prognostics and therapy" – Karolinska Institutet, Sweden – invited oral presentation (Prof. Samir El-Andaloussi)
Revolutionizing Next-Generation Sequencing: Tools and Technologies – Leuven, Belgium
Mini-symposium on RNA-sequencing – Ghent, Belgium
Symposium 'The immune-brain axis: from molecules to behavior' – Hasselt, Belgium
COST meeting 'MouseAge' - Braga, Portugal
Symposium 'Emerging Cytokine Networks' – Ghent, Belgium
IUAP meeting – Ghent, Belgium
'ER Stress & Inflammation meeting 2015' – Ghent, Belgium
IRC-FWO minisymposium on 'Molecular Mechanisms of Inflammation' – Ghent, Belgium

2016

TAC meeting on Lung Diseases – Lucerne, Switzerland – invited oral presentation
2nd GGIG meeting – Ghent, Belgium
COST meeting ‘MouseAge’ – Madrid, Spain – poster presentation
International Society of Extracellular Vesicles (ISEV) meeting 2016 – Rotterdam, The Netherlands – session chair
VIB seminar 2016 – Blankenberge, Belgium – poster presentation
WPC 2016 ‘Blood brain barrier’ – Boston, MA, USA – poster presentation
Gordon Research Seminar - Barriers of the CNS – New London, NH, USA – poster presentation
Gordon Research Conference - Barriers of the CNS – New London, NH, USA – oral and poster presentation
The Brain Mosaic: cellular heterogeneity in the CNS – Leuven, Belgium
IRC symposium ‘Innate immunity & lymphoid homeostasis symposium’ – Ghent, Belgium
Symposium on Multiple Sclerosis – Ghent, Belgium
Multinational joint Franco-Italian-Swiss meeting on Blood-brain interfaces – Lyon, France – oral presentation
COST meeting ‘MouseAge’ – Vienna, Austria
BIS meeting – Brussel, Belgium – invited oral presentation
1st International Symposium Research on Healthy Ageing – Lille, France

2017

Gordon Research Conference - Neuroimmune Communication in Health & Disease – Ventura, CA, USA – oral presentation
ER Stress, Autophagy & Immune System conference – Bruges, Belgium
Kickoff meeting B-smart Horizon 2020 project – Utrecht, The Netherlands
Nederlandse Anatomenvereniging (NAV) – Lunteren, The Netherlands – invited oral presentation
Belgian Week of Gastroenterology – Antwerp, Belgium – invited oral presentation
Seminar – Rudjer Boskovic Institute – Zagreb, Croatia – invited oral presentation
Neuroinflammation and Ageing meeting – Dublin, Ireland – invited oral presentation
BBBNedwork meeting – Leiden, The Netherlands – invited oral presentation
CNS barrier congress – London, UK – invited oral presentation
Symposium on Sepsis – Ghent, Belgium – invited oral presentation
BioimagingUser Group meeting – Ghent, Belgium – invited oral presentation
VIB seminar 2017 – Veldhoven, the Netherlands – invited oral presentation
‘Extracellular Vesicle’ session – Nantes, France – invited oral presentation
International Society of Extracellular Vesicles (ISEV) meeting 2017 – Toronto, Canada – oral presentation
12th International Conference on Cerebral Vascular Biology (CVB 2017) – Melbourne, Australia – invited oral presentation

Jury member PhD

- 2015** Dr. Miguel Cardoso, Faculty of Sciences, Ghent University
2016 Dr. Eva Ramboer, Faculty of Pharmacy, VUB
Dr. Chen Liu, Faculty of Veterinary Sciences, Ghent University
Dr. Sarah Devriese, Faculty of Medicine, Ghent University
Dr. Stephan Stremersch, Faculty of Pharmaceutical Sciences
2017 Dr. Freya Joris, Faculty of Pharmacy, Ghent University
Caroline Blaecher, Faculty of Veterinary Sciences, Ghent University (planned October 2016)

Guidance Master students

2002-2003

Claire Rodwell (Industrial Engineering Hogeschool Sint-Lieven)
Els Vanderleyden (2nd master Biomedical Engineering UGent)

2003-2004

Kevin Buyens (1st master Pharmaceutical Sciences UGent)

2004-2005

Ieme Blondeel (master Industrial Engineering BME)
Heleen Devenijn (1st master Pharmaceutical Sciences UGent)
Marie-Luce De Temmerman (1st master Pharmaceutical Sciences UGent)

2005-2006

Barbara Geussen (2nd master Biomedical Engineering UGent)
Maarten Colman (master Industrial Engineering BME)

2006-2007

Deborah Morel (technician KaHo Sint-Lieven)
Charlotte De Visscher (1st master Pharmaceutical Sciences UGent)

2009-2010

Evi Galley (master Industrial Engineering BME)
Evy Goossen (2nd master Biotechnology UGent)
Glynis De Clercq (1st master Biomedical Sciences UGent)
Guillaume Tahon (3rd bachelor Industrial Engineering BME)

2010-2011

Glynis De Clercq (2nd master Biomedical Sciences UGent)
Guillaume Tahon (master Industrial Engineering BME)
Sophie Steeland (1st master Pharmaceutical Sciences UGent)
Bachelor exercise 1st master Biotechnology UGent (4 students)

2011-2012

Sofie Lodens (master Industrial Engineering BME)
Eline Dhondt (1st master Pharmaceutical Sciences UGent)
Annelien Vanderhaeghe (2nd master Biotechnology UGent)
Bachelor exercise 2nd bachelor Biotechnology UGent (3 students)

2012-2013

Yael Vandenbussche (2nd master Bioengineering option gene technologie UGent)
Nele Beelaert (master Industrial Engineering BME)

2013-2014

Nina Gorlé (2nd master Biotechnology UGent)
Charysse Vandendriessche (1st master Biomedical Sciences UGent)

2014-2015

Charysse Vandendriessche (2nd master Biomedical Sciences UGent)
Sara Reynout (2nd master Biotechnology UGent)
Sarah Van Belleghem (1st master Biomedical Sciences UGent)

2015-2016

Sarah Van Belleghem (2nd master Biomedical Sciences UGent)
Eline De Rore (2nd master Biotechnology UGent)
Marie Pauwels (1st master Biomedical Sciences UGent)

2016-2017

Nele Plehiers (2nd master Biotechnology UGent)
Marie Pauwels (2nd master Biomedical Sciences UGent)
Martijn Giraldo (Professional Bachelor Odyssee Gent)

Teaching

2003-2008

Introduction to 'Excel' (2nd bachelor Pharmacy)

Guidance practical exercises 'Algemene Biochemie' (2nd bachelor Pharmacy)

Guidance practical exercises 'Fysicochemie van het Geneesmiddel' (2nd bachelor Pharmacy)

PGO sessions 'Biochemie' about "DNA" (2nd bachelor Pharmacy)

2010-2011

Guidance practical exercises and course 'Voedingswarenanalyse' (2nd bachelor Voedings- en dieetkunde)

2011-2012

Guidance practical exercises and course 'Levensmiddelenchemie' (2nd bachelor Voedings- en dieetkunde)

2014-2015

Integrated practical course (3rd bachelor Biotechnology UGent)

Bachelor projects (1st master Biotechnology UGent)

2015-2016

Integrated practical course (3rd bachelor Biotechnology UGent)

2016-2017

Integrated practical course (3rd bachelor Biotechnology UGent)

Moleculaire celbiologie (2nd bachelor Biotechnology UGent)